Table 2.
Association of intensive treatment versus standard treatment on plasma biomarkers adjusted for kidney function and blood pressure
| Adjusted for eGFR | Intensive Treatment | Standard Treatment | ||||
|---|---|---|---|---|---|---|
|
| ||||||
| Biomarker | Baseline Mean (95% CI) |
Change / Year (95% CI) |
Baseline Mean (95% CI) |
Change / Year (95% CI) |
Difference (95% CI) |
P value |
|
| ||||||
| Aβ40 (pg/ml) | 216.7 (173.8, 259.5) |
7.6 (4.8, 10.3) |
208.7 (165.6, 251.7) |
6.6 (3.6, 9.7) |
1.0 (−3.1, 5.0) |
0.65 |
| Aβ42 (pg/ml) | 22.1 (18.6, 25.6) |
0.7 (0.5, 0.9) |
21.2 (17.7, 24.7) |
0.7 (0.4, 0.9) |
0.0 (−0.3, 0.3) |
0.89 |
| Aβ42 / Aβ40 | 0.118 (0.079, 0.156) |
0.000 (−0.001, 0.001) |
0.122 (0.083, 0.161) |
0.000 (−0.002, 0.001) |
0.001 (−0.001, 0.002) |
0.43 |
| Total Tau (pg/ml) | 8.1 (7.5, 8.6) |
0.0 (−0.1, 0.1) |
8.0 (7.5, 8.5) |
0.0 (−0.1, 0.1) |
0.0 (−0.1, 0.1) |
0.96 |
| NfL (pg/ml) | 16.8 (14.1, 19.6) |
1.1 (0.6, 1.7) |
16.8 (14, 19.5) |
1.1 (0.5, 1.7) |
0.0 (−0.8, 0.8) |
0.92 |
|
| ||||||
| Adjusted for SBP | Intensive Treatment | Standard Treatment | ||||
|
| ||||||
| Biomarker | Baseline Mean (95% CI) |
Change / Year (95% CI) |
Baseline Mean (95% CI) |
Change / Year (95% CI) |
Difference (95% CI) |
P value |
|
| ||||||
| Aβ40 (pg/ml) | 212.4 (168.8, 256.0) |
11.2 (8.3, 14.0) |
206.3 (162.4, 250.1) |
7.7 (4.7, 10.7) |
3.5 (−0.6, 7.5) |
0.09 |
| Aβ42 (pg/ml) | 21.9 (18.6, 25.3) |
0.9 (0.7, 1.1) |
21.2 (17.8, 24.6) |
0.7 (0.5, 0.9) |
0.2 (−0.1, 0.5) |
0.27 |
| Aβ42 / Aβ40 | 0.12 (0.08, 0.16) |
−0.001 (−0.002, 0.001) |
0.12 (0.08, 0.16) |
−0.001 (−0.002, 0.001) |
0.000 (−0.002, 0.002) |
0.97 |
| Total Tau (pg/ml) | 8.0 (7.5, 8.5) |
0.1 (0.0, 0.2) |
8.0 (7.5, 8.6) |
0.0 (0.0, 0.1) |
0.1 (−0.1, 0.2) |
0.23 |
| NfL (pg/ml) | 15.6 (13.2, 18.0) |
2.1 (1.7, 2.4) |
16.4 (13.9, 18.9) |
1.3 (0.9, 1.6) |
0.8 (0.3, 1.3) |
0.001 |
|
| ||||||
| Adjusted for DBP | Intensive Treatment | Standard Treatment | ||||
|
| ||||||
| Biomarker | Baseline Mean (95% CI) |
Change / Year (95% CI) |
Baseline Mean (95% CI) |
Change / Year (95% CI) |
Difference (95% CI) |
P value |
|
| ||||||
| Aβ40 (pg/ml) | 211.4 (168.4, 254.4) |
9.5 (6.7, 12.3) |
206.6 (163.4, 249.9) |
7.1 (4, 10.1) |
2.4 (−1.6, 6.5) |
0.24 |
| Aβ42 (pg/ml) | 21.9 (18.5, 25.3) |
0.8 (0.6, 1.0) |
21.3 (17.9, 24.6) |
0.7 (0.4, 0.9) |
0.1 (−0.2, 0.4) |
0.45 |
| Aβ42 / Aβ40 | 0.12 (0.08, 0.16) |
0.000 (−0.001, 0.001) |
0.12 (0.08, 0.16) |
0.000 (−0.002, 0.001) |
0.000 (−0.001, 0.002) |
0.68 |
| Total Tau (pg/ml) | 8.0 (7.4, 8.5) |
0.1 (0.0, 0.2) |
8.1 (7.5, 8.6) |
0.0 (−0.1, 0.1) |
0.0 (−0.1, 0.2) |
0.45 |
| NfL (pg/ml) | 15.5 (13.2, 17.9) |
1.7 (1.4, 2.1) |
16.6 (14.1, 19.0) |
1.1 (0.8, 1.5) |
0.6 (0.1, 1.1) |
0.03 |
CI denotes confidence interval, DBP diastolic blood pressure, eGFR denotes estimated glomerular filtration rate based on the CKD-EPI equation, NfL neurofilament light chain, and SBP systolic blood pressure. Estimates are from a robust linear mixed model with random effects for participant and batch, adjusting for time since randomization.